Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation

Transplantation

Volumn 98, Issue 2, 2014, Pages 187-194

  Santos, Carlos A Q ^a   Brennan, Daniel C ^a   Fraser, Victoria J ^a   Olsen, Margaret A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Administrative data; Cytomegalovirus; Kidney transplantation

Indexed keywords

ADULT; AGE FACTORS; CALIFORNIA; COMORBIDITY; CONTINENTAL POPULATION GROUPS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLORIDA; GRAFT REJECTION; HOSPITAL MORTALITY; HUMANS; INCOME; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT READMISSION; PROPORTIONAL HAZARDS MODELS; RESIDENCE CHARACTERISTICS; RISK FACTORS; TIME FACTORS;

EID: 84904696541     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000030     Document Type: Article

References (47)

1. Rowshani AT, Bemelman FJ, van Leeuwen EM, et al. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005; 79: 381.
2. Green M. Introduction: infections in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4):3.
3. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4): 93.
4. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
5. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomega-lovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
6. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cyto-megalovirus infection and disease in renal transplant recipients. Tr a n s-plantation 2006; 82(Suppl 2): S15.
7. Eid AJ, Bakri SJ, Kijpittayarit S, et al. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2008; 10: 13.
8. Cordero E, Casasola C, Ecarma R, et al. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplant Proc 2012; 44: 694.
9. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal al-lograft recipients. Transplantation 2000; 70: 1166.
10. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalo virus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
11. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106.
12. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
13. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
14. Hodson EM, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2: CD003774.
15. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461.
16. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cyto-megalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
17. Helantera I, Lautenschlager I, Koskinen P. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009; 24: 316.
18. Helantera I, Kyllonen L, Lautenschlager I, et al. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant 2010; 10: 2026.
19. Cervera C, Fernandez-Ruiz M, Valledor A, et al. Epidemiology and risk factors for late infection in solid organ transplant recipients. Transpl Infect Dis 2011; 13: 598.
20. Boobes Y, Al HM, Dastoor H, et al. Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports. Transplant Proc 2004; 36: 1841.
21. Blyth D, Lee I, Sims KD, et al. Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation. Transpl Infect Dis 2012; 14: 149.
22. Israni AK, Snyder JJ, Skeans MA, et al. Who is caring for kidney transplant patients? Variation by region, transplant center, and patient characteristics. Am J Nephrol 2009; 30: 430.
23. Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis 2011; 13: 244.
24. Harvala H, Stewart C, Muller K, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 2013; 85: 893.
25. Immunosuppressive therapy for renal transplanation in adults. NHS National Institute for Clinical Excellence 2013. Available at: URL: www.nice.org.uk/TA085guidance. Accessed December 13, 2013.
26. Eid AJ, Arthurs SK, Deziel PJ, et al. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010; 10: 157.
27. Eid AJ, Razonable RR. New developments in the management of cy-tomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965.
28. Wong KM, Chan YH, Chan SK, et al. Cytomegalovirus-induced tubulointerstitial nephritis in a renal allograft treated by foscarnet therapy. Am J Nephrol 2000; 20: 222.
29. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18.
30. Conti DJ, Freed BM, Singh TP, et al. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg 1995; 130: 1217.
31. Abbott KC, Hypolite IO, Viola R, et al. Hospitalizations for cyto-megalovirus disease after renal transplantation in the United States. Ann Epidemiol 2002; 12: 402.
32. Patzer RE, Pastan SO. Measuring the disparity gap: quality improvement to eliminate health disparities in kidney transplantation. Am J Transplant 2013; 13: 247.
33. Patzer RE, McClellan WM. Influence of race, ethnicity and socio-economic status on kidney disease. Nat Rev Nephrol 2012; 8: 533.
34. Pescovitz MD. Formulary considerations for drugs used to prevent cytomegalovirus disease. Am J Health Syst Pharm 2003; 60(23 Suppl 8): S17.
35. Amano H, Yamamoto H, Senba M, et al. Impairment of endotoxin-induced macrophage inflammatory protein 2 gene expression in alveolar macrophages in streptozotocin-induced diabetes in mice. Infect Immun 2000; 68: 2925.
36. Delamaire M, Maugendre D, Moreno M, et al. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14: 29.
37. Zykova SN, Jenssen TG, Berdal M, et al. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000; 49: 1451.
38. Mazade MA, Edwards MS. Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neu-trophils in diabetes. Mol Genet Metab 2001; 73: 259.
39. Ilyas R, Wallis R, Soilleux EJ, et al. High glucose disrupts oligosac-charide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology 2011; 216: 126.
40. Price CL, Hassi HO, English NR, et al. Methylglyoxal modulates immune responses: relevance to diabetes. J Cell Mol Med 2010; 14: 1806.
41. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988Y2004. Clin Infect Dis 2010; 50: 1439.
42. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214.
43. Matas AJ, Gillingham KJ, Payne WD, et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857.
44. Opelz G, Dohler B. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85: 661.
45. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8.
46. SEER Medicare 2013. Available at: http://healthservices.cancer.gov/ seermedicare/program/charlson.comorbidity.macro.txt. Accessed August 13, 2013.
47. David Schoenfeld. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239.